Interview with Warren Chen, Country Manager, Celgene Taiwan
Could you please give our readers an overview of the importance of Taiwan for Celgene in a regional and a global context? What is attractive in Taiwan for Celgene? Celgene…
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With $1.5 billion in assets under management, the firm’s businesses include venture capital/private equity, merchant banking, and media. By leveraging the scientific and business networks of its team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, transactional support, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia.
G. Steven Burrill founded Burrill & Company as a logical extension of his 40-year involvement in the growth and prosperity of the biotechnology industry. Mr. Burrill has been an active advisor and catalyst in some of the industry’s most notable companies and transactions. Mr. Burrill’s close involvement and respected position within the industry has positioned the firm as a prominent deal-maker and facilitator of industry partnerships and alliances, all of which fosters a robust deal flow. Further contributing to this deal flow are: the scientific and business networks of its investment team; the Advisory Boards; the strategic and financial network of its limited partners; and the close relationships developed with numerous life science companies and management as a result of Burrill’s visibility, reputation, and the firm’s partnering and alliance work.
Could you please give our readers an overview of the importance of Taiwan for Celgene in a regional and a global context? What is attractive in Taiwan for Celgene? Celgene…
Novo Nordisk is one of the few pharmaceutical multinationals focused in one key therapeutic area. Perhaps you could start by telling our readers about how diabetes has evolved in Taiwan…
Please tell our readers about the importance of GSK Taiwan within the context of the company’s global operations, and also what there is in Taiwan that makes it so attractive…
Medigen was created in 1999 and is a listed company. How did the vision for the company come about, and what was it that attracted today’s main shareholders to Medigen?…
Please describe the activities of the IRPMA to our readers, and explain the membership advantages of your association. Today the IRPMA consists of 37 multinational research-based pharmaceutical manufacturers, as well…
The Development Centre for Biotechnology was founded in 1984 as a tool for connecting biotechnological academia to the Taiwanese industry and promoting the strengths of Taiwan’s biopharmaceutical sector to the…
Please explain the factors that led to the creation of the Taiwan Intellectual Property Office, and its main activities today. For the Taiwanese government, intellectual property (IP) rights are very…
Genovate was founded in 1995. It is a very interesting story: a mix of biotech, the history with American company Genelabs, government investments and also private investment through Chinachem. Can…
See our Cookie Privacy Policy Here